We spoke to Carl V Hill, PhD, MPH, chief diversity, equity and inclusion officer of the Alzheimer’s Association about the results of the Alzheimer’s Association report, 2021 Alzheimer’s Disease Facts and Figures.
The researchers sought to understand the prognostic value of tau positron emission tomography for predicting cognitive decline across the clinical spectrum of Alzheimer disease.
Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer disease drug with a high price tag and unproven benefits that have prompted widespread controversy.
The researchers conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with dominantly inherited Alzheimer disease across asymptomatic and symptomatic disease stages.
The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer disease medication Aduhelm that will likely limit its use.
The researchers hypothesized that as the participants became older adults, their cognitive functioning would decline more steeply relative to earlier assessments.
